Stay updated on LY2880070 in Advanced Cancer Clinical Trial
Sign up to get notified when there's something new on the LY2880070 in Advanced Cancer Clinical Trial page.

Latest updates to the LY2880070 in Advanced Cancer Clinical Trial page
- Check2 days agoChange DetectedAdded a consolidated Locations section listing sites in Massachusetts, Michigan, Alberta, British Columbia, Ontario, and Quebec, and removed the old per-location subsections for those regions.SummaryDifference0.5%

- Check10 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page now displays Revision: v3.3.2, replacing Revision: v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check32 days agoChange DetectedAdded clarifications that publications are provided voluntarily by the study team and are automatically filled from PubMed, and updated the revision metadata to v3.3.1. Removed older wording describing PubMed-generated publications and the reference to revision v3.2.0; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check40 days agoChange DetectedRemoved the banner about government funding and NIH operating status. The study details, eligibility criteria, and locations remain unchanged.SummaryDifference0.3%

- Check54 days agoChange DetectedAdded a related publication abstract LY2880070 with gemcitabine in cancer (ASCO 2020), the sponsor Esperas Pharma Inc., and a note for Helpful Links Provided by Esperas Pharma Inc.; to avoid alerts for small changes, set an alert condition below.SummaryDifference0.4%

- Check82 days agoChange Detected- Added a government operating status notice and a link to official sources for NIH Clinical Center status. - Updated version to v3.2.0 and removed reference to v3.1.0.SummaryDifference3%

Stay in the know with updates to LY2880070 in Advanced Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LY2880070 in Advanced Cancer Clinical Trial page.